Skip to content

    This content is selected and controlled by WebMD's editorial staff and is brought to you by Grifols.

    Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neurological disorder -- a condition that targets your body’s nerves.

    Symptoms aren’t the same for everyone, but you may be tired and have areas of numbness and pain. It can slow your reflexes and make your arms and legs feel weak. You have to have symptoms for at least 8 weeks for CIDP to be considered the cause.

    Most people need treatment. And the sooner you begin it, the better the chance of a complete recovery. Sometimes symptoms go away for a long time but come back later.

    Anyone can get CIDP, but it’s most common in older adults, and more in men than women. As many as 40,000 people in the U.S. may have the condition, but it’s hard to know how many people have it. CIDP isn’t easy to diagnose.

    What causes it?

    Experts aren’t sure why people get the disorder. What they do know is that it’s caused by inflammation of nerves and nerve roots. The swelling can destroy the protective covering around nerves, known as myelin. That can hurt nerve fibers and slow the nerves’ ability to send signals. This is what causes the weakness, pain, fatigue, and numbness.

    Is it the same as Guillain-Barre syndrome?

    No. CIDP is closely related to Guillain-Barre syndrome (GBS). Both are nerve problems, and both cause symptoms such as weakness and numbness. But GBS usually comes on days or weeks after a person has an illness, such as a stomach bug. CIDP isn’t linked to illness. With GBS, once treated, most people recover fairly quickly. CIDP, on the other hand, tends to be a longer-term problem. In rare cases, people who don’t recover from GBS may develop CIDP.

    How is it diagnosed?

    There’s no test to diagnosis CIDP. Instead, your doctor will ask you questions about your symptoms, such as when they started and how they feel. He’ll do a thorough physical examination and may also recommend tests to get a better idea of what’s going on with your nerves, and to rule out other possible causes.

    In some cases, doctors can’t be completely sure it’s CIDP, but they may go ahead and start treatment. If the symptoms improve, that’s strong evidence it’s CIDP.

    Weakness, Numbness, or Tingling? You Could Have CIDP

    • CIDP is a neurological disorder characterized by fatigue and/or progressive weakness, tingling, or numbness in the arms and legs. GAMUNEX-C may help reduce symptoms.

    Important Safety Information

    GAMUNEX®-C (immune globulin injection [human], 10% caprylate/chromatography purified) is approved to treat primary humoral immunodeficiency disease (PIDD) in patients 2 years of age and older. If you have PIDD, you may take GAMUNEX-C under the skin (subcutaneously) or in a vein (intravenously). GAMUNEX-C is also approved to treat idiopathic thrombocytopenic purpura (ITP) and chronic inflammatory demyelinating polyneuropathy (CIDP). If you have ITP or CIDP, you may only take GAMUNEX-C intravenously.


    If you take GAMUNEX-C or a similar immune globulin product, you could experience a serious and life-threatening blood clot (thromboembolism), which may include pain and/or swelling of an arm or leg with warmth over the affected area, discoloration of an arm or leg, unexplained shortness of breath, chest pain or discomfort that worsens on deep breathing, unexplained rapid pulse, numbness, or weakness on one side of the body. You are more likely to develop a blood clot if you have a history of hardening of the arteries (atherosclerosis), stroke, heart attack, or heart failure (low volume of blood pumped by the heart). You may also be more likely to get a blood clot if you are elderly, if you have a blood clotting disorder, if you are inactive for long periods of time (such as long bed rest), if you use estrogens, or if you have thickening of your blood. For patients at risk, GAMUNEX-C should be administered at the lowest dose and slowest infusion rate that is practical. However, blood clots may occur in the absence of any of the known risk factors. Patients should be well hydrated by drinking enough water before GAMUNEX-C is administered. Tell your doctor immediately if your medical history is similar to what is described here, and especially if you start having any of these symptoms while taking GAMUNEX-C.


    If you take GAMUNEX-C or a similar immune globulin product intravenously, you could experience serious kidney disease and death. You may have symptoms of decreased urination, sudden weight gain, swelling in your legs (edema), or shortness of breath. You are more likely to develop serious kidney disease if you already have a kidney problem, have Type II diabetes mellitus, or are older than 65. You are more likely to develop serious kidney disease if you are dehydrated, have a blood infection (sepsis), have high protein content in your blood, or if you are receiving other medicines that are harmful to your kidneys. Tell your doctor immediately if your medical history is similar to what is described here, and especially if you start having any of these symptoms while taking GAMUNEX-C.


    You are more likely to develop serious kidney disease if you take an intravenous immune globulin product that contains sugar (sucrose). GAMUNEX-C does not contain sugar. If your situation makes you more likely to experience serious kidney disease, you should take GAMUNEX-C at the lowest concentration available and the slowest infusion rate that is practical.


    Do not take GAMUNEX-C if you have an allergy to immune globulin. Tell your doctor if you have had a serious reaction to other medicines that contain human immune globulin. Also tell your doctor if you have immunoglobulin A (IgA) deficiency. If you have a serious reaction while taking GAMUNEX-C, stop taking it immediately and tell your doctor.


    Periodic monitoring of kidney function and urine output is particularly important in patients more likely to experience severe kidney disease.


    You could experience other serious and life-threatening problems due to immune globulin. You could get a lung problem called transfusion-related acute lung injury, also known as TRALI, or have fluid in the lungs (pulmonary edema) that is not the result of heart failure. You could get a blood problem called hemolytic anemia (common symptoms include increased heart rate, fatigue, yellow skin or eyes, and dark-colored urine). You could get aseptic meningitis, a type of brain inflammation with symptoms of severe headache, stiff neck, fatigue, fever, sensitivity to light, painful eye movements, nausea, and vomiting.


    If you have higher than normal body fluid volumes or if you have a condition where increasing body fluid volume may be a concern, a higher dose, such as 1g/kg for 1-2 days, is not recommended.


    Because GAMUNEX-C is made from human blood, it may carry a risk of transmitting infectious agents such as viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.


    You may not take GAMUNEX-C subcutaneously if you have ITP. If you have ITP and take GAMUNEX-C subcutaneously, you could experience a very serious and life-threatening black and blue wound (hematoma, which is a pocket of blood within a tissue).


    After you take GAMUNEX-C, your blood antibody levels may rise, which could cause some blood antibody tests to give false results.


    The most common side effects in a clinical study with PIDD patients who got subcutaneous injections of GAMUNEX-C were redness, swelling and itching at the infusion site, headache, flu, fatigue, pain (including pain in the back, joints, arms, and legs), and fever. In clinical studies with PIDD patients who got GAMUNEX-C intravenously, the most common side effects were headache, cough, nausea, inflammation of the throat (which is the most common cause of sore throat), and rash and redness, swelling and itching at the injection site. In a clinical study with CIDP patients who got GAMUNEX-C intravenously, the most common side effects were headache, fever, chills, high blood pressure, rash, nausea, and physical weakness. In clinical trials with ITP patients who got GAMUNEX-C intravenously, the most common side effects were headache, vomiting, fever, nausea, back pain, and rash.


    The most serious side effects in clinical studies were a blood clot to the lung (pulmonary embolism) in 1 patient with a history of this condition (in CIDP), a flare-up of an existing type of anemia (autoimmune pure red cell aplasia) in 1 patient (in PIDD), and heart inflammation (myocarditis) in 1 patient (in ITP).


    Please see accompanying full Prescribing Information for GAMUNEX-C.


    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.


    © 2016 Grifols. All rights reserved.


    US/GX/1215/0191 (1)